The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

Por Stellbrink, HJ, Rugina, S, Zagler, C, Esser, S, Castagna, A, Gazzard, B, Hill, A, van Delft, Y, Marks, S
Publicado em 2010